BiotechTube
Character Biosciences

Character Biosciences

Pre-clinical
San Francisco, United StatesFounded 202150-100 employeescharacterbio.com

Character Biosciences is a private, clinical-stage biotech company pioneering a data-driven approach to treat complex polygenic diseases. By integrating genomics, longitudinal clinical data, imaging, and AI, the company identifies patient subtypes and genetic drivers of disease progression to develop more precise therapeutics. The company has built a robust pipeline with candidates in Phase 1 for dry AMD and geographic atrophy, secured Series B funding from top-tier investors, and assembled a seasoned leadership team with expertise in drug discovery, data science, and clinical development.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $109M

AI Company Overview

Character Biosciences is a private, clinical-stage biotech company pioneering a data-driven approach to treat complex polygenic diseases. By integrating genomics, longitudinal clinical data, imaging, and AI, the company identifies patient subtypes and genetic drivers of disease progression to develop more precise therapeutics. The company has built a robust pipeline with candidates in Phase 1 for dry AMD and geographic atrophy, secured Series B funding from top-tier investors, and assembled a seasoned leadership team with expertise in drug discovery, data science, and clinical development.

OphthalmologyRetinal DiseasesNeurodegenerative Diseases

Technology Platform

An integrated data platform combining human genomics, longitudinal clinical/imaging data, and AI to identify patient subtypes and genetic drivers of disease progression for precision drug discovery and development.

Funding History

3
Total raised:$109M
PIPE$93MMar 25, 2025
Series A$12MNov 15, 2022
Seed$4MMay 15, 2021

Opportunities

Validating its polygenic risk scores in ongoing Phase 1 trials could create a powerful companion diagnostic strategy, de-risking later development and enabling premium pricing.
The platform is potentially expandable to other polygenic diseases beyond ophthalmology, such as cardiovascular or metabolic disorders, offering long-term pipeline growth.

Risk Factors

The core risk is clinical failure of its lead assets, which would also challenge validation of its precision medicine platform.
The company faces intense competition in the AMD space from large pharma and well-funded biotechs.
As a private company, it remains dependent on future financing rounds in a potentially volatile capital market.

Competitive Landscape

Character Bio competes in the crowded AMD therapeutic space against companies like Apellis, Astellas, Regeneron, and Novartis. Its key differentiation is its genetics-driven platform designed to identify responsive patient subtypes, aiming for higher efficacy in targeted populations compared to broader-acting therapies.